Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
10.37
+0.11 (1.07%)
Dec 26, 2025, 4:00 PM EST - Market closed
Cullinan Therapeutics Employees
Cullinan Therapeutics had 111 employees as of December 31, 2024. The number of employees increased by 26 or 30.59% compared to the previous year.
Employees
111
Change (1Y)
26
Growth (1Y)
30.59%
Revenue / Employee
n/a
Profits / Employee
-$1,953,270
Market Cap
612.62M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 111 | 26 | 30.59% |
| Dec 31, 2023 | 85 | 23 | 37.10% |
| Dec 31, 2022 | 62 | 31 | 100.00% |
| Dec 31, 2021 | 31 | 7 | 29.17% |
| Dec 31, 2020 | 24 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CGEM News
- 18 days ago - Cullinan Therapeutics, Inc. (CGEM) Discusses Initial CLN-049 Results and Development Strategy for AML Applications Transcript - Seeking Alpha
- 19 days ago - Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting - GlobeNewsWire
- 26 days ago - Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia - GlobeNewsWire
- 5 weeks ago - Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations - PRNewsWire
- 6 weeks ago - Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting - GlobeNewsWire
- 7 weeks ago - Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 7 weeks ago - Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting - GlobeNewsWire
- 2 months ago - Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025 - GlobeNewsWire